Prevalence of comorbid asthma in Tunisian patients with COVID-19: clinical features and outcomes

J Infect Dev Ctries. 2023 Dec 31;17(12):1706-1713. doi: 10.3855/jidc.17485.

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in around 1 million COVID-19 infection cases and over 29,000 deaths in Tunisia thus far. There is great variability in the prevalence of asthma among patients with COVID-19, but the impact of asthma on patients with COVID-19 is not clear. We sought to describe the clinical features of Tunisian patients with COVID-19 and to compare asthmatic and non-asthmatic patients.

Methodology: This retrospective study included 675 Tunisian patients who were hospitalized with COVID-19. Clinical characteristics were collected from medical records. Bivariate analyses and multivariate regression models were used to assess the associations between asthma and the risk of severe symptoms, including death/recovery.

Results: The prevalence of asthma in the sample was 14.5%. The results show that asthmatic patients with COVID-19 have significantly less severe symptoms and better outcomes than non-asthmatic patients.

Conclusions: Asthma was not found to be associated with higher severity or worse prognosis among patients with COVID-19 in Tunisia.

Keywords: COVID-19; asthma; comorbidity; severity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma* / complications
  • Asthma* / epidemiology
  • COVID-19* / epidemiology
  • Humans
  • Prevalence
  • Retrospective Studies
  • SARS-CoV-2